321574-99-6

Upstream product

• 13472-00-9 p-Aminophenethylamine 
• 122797-04-0 (S)-{[4-(Phenylmethoxy)phenoxy]methyl}-oxirane 
• 103-16-2 4-Benzyloxyphenol 

Downstream Products

• 321575-01-3 tert-butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate 
• 321575-02-4 tert-butyl (2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamate 
• 321575-04-6 tert-butyl-(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl{4-[(4-bromobenzyl)amino]phenethyl}carbamate 
• 391902-03-7 tert-butyl (2 S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl[4-(methylamino)phenethyl]carbamate 
• 209180-77-8 4-{(S)-3-[2-(4-Amino-phenyl)-ethylamino]-2-hydroxy-propoxy}-phenol 

Relevant academic research and scientific papers

Azolidines as beta-3 adrenergic receptor agonists

This invention provides compounds of Formula I having the structure wherein, A, X, Y, Z, W, R1, R2, R3, R4, R5, and R6 are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

Potent, selective aminothiazolidinediones agonists of the human β3 Adrenergic receptor

A cloned human β3 adrenergic receptor assay was used to identify potent and selective β3 agonists. The thiazolidinedione moiety has been identified as a new pharmacophore for the human β3 adrenergic receptor. The versatility of the thiazolidinedione pharmacophore was demonstrated in both the arylethanolamine and phenylpropanolamine families of β3 agonists, where potent and selective compounds have been synthesized. Thiazolidinedione 20, a potent and selective human β3 agonist, increased thermogenesis and lowered plasma glucose levels in the db/db mice.

Potent, selective benzenesulfonamide agonists of the human β3 adrenergic receptor

A cloned human β3 adrenergic receptor assay was used to identify phenoxypropanolamine agonist 1. SAR, studies led to the identification of benzenesulfonamide derivative 20, a 6.3 nM β3 agonist which shows 30-fold selectivity for β3 agonist activity over β1 and β2 receptor binding. Further refinement of this lead provided 4-bromo derivative 39, a subnanomolar agonist with 660-fold and 230-fold selectivity over β1 and β2, respectively.